Employer profile
Omeros CORP
3 open roles indexed with location, benefit, and apply-link signals where available.
Open roles
Showing the most recent indexed roles for this employer.
-
Director, AI Innovation & Partnerships
Seattle, WA, United States
unspecified $215K-$235KDirector, AI Innovation & Partnerships Seattle, WA, United States We are a fast-growing and dynamic organization seeking a DirectorAI Innovation & Partnerships to join our team. The Director AI Innovation & Partnerships builds and directs a portfolio of cross-functional AI use cases across the company, including discovery through clinical development, regulatory/QA, CMC, Commercial, and Corporate functions. The role translates scientific and business needs into technical capabilities and automated solutions. Position is responsible for developing and managing strategic external AI-focused partnerships to advance the company's programs and functions . Position reports to Associate VP of Structural Biology with dotted line reporting into CBDO and CEO. Good things are happening at Omeros! Who is Omeros? Omeros is an innovative biotechnology company that discovers, develops, and commercializes first-in-class small-molecule and protein therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros' lead lectin pathway inhibitor YARTEMLEA ® , which inhibits the pathway's effector enzyme MASP-2, is FDA-approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients ages two years and older, with a planned U.S. launch in January 2026. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review by the European Medicines Agency, with a decision expected in mid-2026. OMS1029, Omeros' long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical
-
Medical Director / Sr. Medical Director, Clinical Development
Seattle, WA, United States
unspecified $270K-$305KMedical Director / Sr. Medical Director, Clinical Development Seattle, WA, United States We are a fast-growing and dynamic organization seeking a Medical Director / Sr Medical Director to join our Clinical Development team. The Medical Director / Sr Medical Director will play a key role at all stages of clinical development. The successful candidate will have oversight for planning and execution of clinical trials and be involved in the exploration of novel indications. The role will provide clinical leadership to cross-functional project teams on development strategies, clinical study outlines and protocols. Compilation and interpretation of study results and interfacing with multiple cross-functional areas including clinical operations, safety, medical and scientific communications, commercial (marketing, sales, managed markets), regulatory, product manufacturing and supply will be key responsibilities, as well as communication and interpretation with external partners, clinical investigators and Key Opinion Leaders. Good things are happening at Omeros! Who is Omeros? Omeros is an innovative biotechnology company that discovers, develops, and commercializes first-in-class small-molecule and protein therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros' lead lectin pathway inhibitor YARTEMLEA ® , which inhibits the pathway's effector enzyme MASP-2, is FDA-approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients ages two years and older, with a planned U.S. launch in January 2026. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review by the European Medicines Agency, with a decision expected in
-
Director, Quality Control
Seattle, WA, United States
unspecified $210K-$245KDirector, Quality Control Seattle, WA, United States We are a fast-growing and dynamic organization seeking a Director, Quality Control to join our CMC team. The Director, Quality Control will provide strategic leadership in managing a growing team of scientists responsible for QC-related activities and operations. This individual will be responsible for providing scientific leadership, defining QC strategy and determining a roadmap for QC related activities and operations to meet corporate objectives. The scope of this role covers all phases of product development (clinical and commercial) at Omeros for both large and small pharmaceutical products. Good things are happening at Omeros! Who is Omeros? Omeros is an innovative biotechnology company that discovers, develops, and commercializes first-in-class small-molecule and protein therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros' lead lectin pathway inhibitor YARTEMLEA ® , which inhibits the pathway's effector enzyme MASP-2, is FDA-approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients ages two years and older, with a planned U.S. launch in January 2026. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review by the European Medicines Agency, with a decision expected in mid-2026. OMS1029, Omeros' long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications, along with